Mean Platelet Volume as a Prognostic Marker in Metastatic Colorectal Cancer Patients Treated with Bevacizumab-Combined Chemotherapy |
Tunce, Tolga
(Department of Medical Oncology, Gata Haydarpasa Training Hospital)
Ozgun, Alpaslan (Department of Medical Oncology, Gata Haydarpasa Training Hospital) Emirzeoglu, Levent (Department of Medical Oncology, Gata Haydarpasa Training Hospital) Celik, Serkan (Department of Medical Oncology, Gata Haydarpasa Training Hospital) Bilgi, Oguz (Department of Medical Oncology, Gata Haydarpasa Training Hospital) Karagoz, Bulent (Department of Medical Oncology, Gata Haydarpasa Training Hospital) |
1 | Amado RG, Wolf M, Peeters M, et al (2008). Wild type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol, 26, 1626-34. DOI ScienceOn |
2 | Aykan NF, Yildiz I, Sen F, et al (2013). Effect of increased body mass index (BMI) on time to tumour progression (TTP) in unresectable metastatic colorectal cancer patients treated with bevacizumab-based therapy. Med Oncol, 30, 679. DOI ScienceOn |
3 | Bar J, Spencer S, Morgan S, et al (2014). Correlation of lactate dehydrogenase isoenzyme profile with outcome in patients with advanced colorectal cancer treated with chemotherapy and bevacizumab or cediranib: retrospective analysis of the Horizon I study. Clin Colorectal Cancer, 13, 46-53. DOI ScienceOn |
4 | Cai J, Ma H, Huang F, et al (2013). Correlation of bevacizumabinduce hypertension and outcomes of metastatic colorectal cancer patients treated with bevacizumab: a systemeatic review and meta-analysis. World J Surg Oncol, 11, 306. DOI ScienceOn |
5 | Cho SY, Yang JJ, You E, et al (2013). Mean platelet volume/platelet count ratio in hepatocellular carcinoma. Platelets, 24, 375-7. DOI ScienceOn |
6 | Giantonnio B, Catalano B, Meropol N, et al (2007). Bevacizumab in combination with oxaliplatin fluorouracil, and leucoverin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the eastern cooperative oncology group study e3200. J Clin Oncol, 25, 1539-44. DOI ScienceOn |
7 | Hurwitz H, Fehrenbacher L, Novotny W, et al (2004). Bevacizumab plus irinotecan, fluorouracil, and leucoverin for metastatic colorectal cancer. N Engl J Med, 350, 2335-42. DOI ScienceOn |
8 | Inagaki N, Kibata K, Tamaki T, Shimuzu T, Nomura S (2014). Prognostic impact of the mean platelet volume/platelet count ration in terms of survival in advanced non-small cell lung cancer. Lung Cancer, 83, 97-101. DOI ScienceOn |
9 | Jemal A, Center MM, DeSantis C, Ward EM (2010). Global patterns of cancer incidence and mortality rates and trends. Cancer Epidemiol Biomarkers Prev, 19, 1893-7. DOI ScienceOn |
10 | Kabbinavar F, Schulz J, McCleod M, et al (2005). Addition of bevacizumab to bolous fluorouracil and leucoverin in firstline metastatic colorectal cancer: results of a randomized phase II trial. J Clin Oncol, 23, 3697-705. DOI ScienceOn |
11 | Kemal Y, Yucel I, Ekiz K, et al (2014). Elevated serum neutrophil to lymphocyte and platelet to lymphocyte ratios could be useful in lung cancer diagnosis. Asian Pac J Cancer Prev, 15, 2651-4. 과학기술학회마을 DOI ScienceOn |
12 | Kilincalp S, Ekiz F, Basar O, et al (2013). Mean platelet volume could be possible biomarker in early diagnosis and monitoring of gastric cancer. Platelet, early online, 1-3. |
13 | Matowicka-Karna J, Kamocki Z, Polinska B, Osada J, Kemona H (2013). Platelets and inflammatory markers in patients with gastric cancer. Clin Dev Immunol, 2013, 401623. |
14 | Mutlu H, Artis TA, Erden A, Akca A (2013). Alteration in mean platelet volume and placticrit values in patients with cancer that developed thrombosis. Clin Appl Thrombosis/Hemostasis, 19, 331-3. DOI ScienceOn |
15 | Oge T, Yalcin O.T, Ozalp S.S, Isikci T (2013). Platelet volume as a parameter for platelet activation in patients with endometrial cancer. J Obstets Gynecol, 33, 301-4. DOI ScienceOn |
16 | Ozdemir Y, Akin ML, Sucullu I, Balta AZ, Yucel E (2014). Pretreatment neutrophil/lymphocyte ratio as a prognostic aid in colorectal cancer. Asian Pac J Cancer Prev, 15, 2647-50. 과학기술학회마을 DOI ScienceOn |
17 | Dirican A, Varol U, Kucukzeybek Y, et al (2014). Treatment of metastatic colorectalcancer with or without bevacizumab: can the neutrophil/lymphocyte ratio predict the efficiency of bevacizumab? Asian Pac J Cancer Prev, 15, 4781-6. DOI ScienceOn |
18 | Unal D, Eroglu C, Kurtul N, Oguz A, Tasdemir A (2013). Are neutrophil/lymphocyte and platelet/lymphocyte rates in patients with non-small cell lung cancer associated with treatment response and prognosis? Asian Pac J Cancer Prev, 14, 5237-42. 과학기술학회마을 DOI ScienceOn |
19 | Van Custen E, Rivera F, Berry S, et al (2009). Safety and efficacy of fist-line bevacizumab with FOLFOX, XELOX, FOLFIRI and fluropyrmidines in metastatic colorectal cancer: the BEAT study. Ann Oncol, 20, 1842-7. DOI ScienceOn |